Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pieris Pharmaceuticals, Inc. - Common Stock (NQ: PIRS )

13.60 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 13.60
Bid (Size) 9.050 (1)
Ask (Size) 15.00 (2)
Prev. Close 13.60
Today's Range 13.60 - 13.60
52wk Range 6.200 - 22.32
Shares Outstanding 98,935,025
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
From Kahn Swick & Foti, LLC
Via Business Wire
Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
From Palvella Therapeutics
Via GlobeNewswire

Performance

YTD
-8.70%
-8.70%
1 Month
-19.24%
-19.24%
3 Month
-17.53%
-17.53%
6 Month
+55.96%
+55.96%
1 Year
-4.39%
-4.39%

More News

Read More
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
From Palvella Therapeutics
Via GlobeNewswire
Looking Into Pieris Pharmaceuticals's Recent Short Interest
Via Benzinga
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AFBI, ENV, PIRS, BALY on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
PIRS Stock Earnings: Pieris Pharmaceuticals Reported Results for Q2 2024
Via InvestorPlace
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
From Kahn Swick & Foti, LLC
Via Business Wire
Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings
Via Benzinga
Exposures Fossil Fuels
ALLR Stock Alert: Allarity Therapeutics Pushes Shareholders to Back Reverse Split
Via InvestorPlace
Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Why Is Pieris Pharmaceuticals (PIRS) Stock Up 77% Today?
Via InvestorPlace
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement
Via ACCESSWIRE
PIRS Stock Earnings: Pieris Pharmaceuticals Reported Results for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
Via ACCESSWIRE
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
Via ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.